Bioactive Lysophospholipids and Their G Protein-Coupled Receptors

doi:10.1006/excr.1999.4702

Experimental Cell Research

Volume 253, Issue 1, 25 November 1999, Pages 230-238

https://doi.org/10.1006/excr.1999.4702 Get rights and content

Abstract

Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) are serum-borne lysophospholipids that signal through their cognate G protein-coupled receptors to evoke a great variety of responses in numerous cell types. In addition to stimulating cell proliferation and survival, LPA and S1P induce profound cytoskeletal changes through Rho-mediated signaling pathways, leading to such diverse responses as cell rounding, neurite retraction, and modulation of tumor cell invasiveness (transcellular migration). A major recent advance is the identification of a subfamily of heptahelical receptors for LPA and S1P.

References (87)

W.H. Moolenaar
Lysophosphatidic acid, a multifunctional phospholipid messenger
J. Biol. Chem.
(1995)
W.H. Moolenaar et al.
Lysophosphatidic acid: G protein signaling and cellular responses
Curr. Opin. Cell Biol.
(1997)
Y. Yatomi et al.
Sphingosine-1-phosphate: A platelet-activating sphingolipid released from agonist-stimulated human platelets
Blood
(1995)
G. Tigyi et al.
Lysophosphatidates bound to serum albumin activate membrane currents in Xenopus oocytes and neurite retraction in PC12 pheochromacytoma cells
J. Biol. Chem.
(1992)
K. Fukami et al.
Phosphatidic acid that accumulates in platelet-derived growth factor-stimulated Balb/c 3T3 cells is a potential mitogenic signal
J. Biol. Chem.
(1992)
R. Alemany et al.
Formyl peptide receptor signaling in HL-60 cells through sphingosine kinase
J. Biol. Chem.
(1999)
O. Fourcade et al.
Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells
Cell
(1995)
M.C. van Dijk et al.
Exogenous phospholipase D generates lysophosphatidic acid and activates Ras, Rho and Ca²⁺ signaling pathways
Curr. Biol.
(1998)
A.M. Westermann et al.
Malignant effusions contain lysophosphatidic acid (LPA)-like activity
Ann. Oncol.
(1998)
H. Okamoto et al.
EDG1 is a functional sphingosine-1-phosphate receptor that is linked via a Gi/o to multiple signaling pathways, including phospholipase C activation, Ca²⁺ mobilization, Ras-mitogen-activated protein kinase activation, and adenylate cyclase inhibition
J. Biol. Chem.
(1998)

M.J. Lee et al.

Lysophosphatidic acid stimulates the G-protein-coupled receptor EDG-1 as a low affinity agonist

J. Biol. Chem.

(1998)

G. Zhang et al.

Comparative analysis of three murine G-protein coupled receptors activated by sphingosine-1-phosphate

Gene

(1999)

H. Okamoto et al.

EDG3 is a functional receptor specific for sphingosine 1-phosphate and sphingosylphosphorylcholine with signaling characteristics distinct from EDG1 and AGR16

Biochem. Biophys. Res. Commun.

(1999)

S. An et al.

Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid

J. Biol. Chem.

(1998)

N. Ancellin et al.

Differential pharmacological properties and signal transduction of the sphingosine 1-phosphate receptors EDG-1, EDG-3, and EDG-5

J. Biol. Chem.

(1999)

K. Bandoh et al.

Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid

J. Biol. Chem.

(1999)

J. Kon et al.

Comparison of intrinsic activities of the putative sphingosine 1-phosphate receptor subtypes to regulate several signaling pathways in their cDNA-transfected Chinese hamster ovary cells

J. Biol. Chem.

(1999)

R.T. Windh et al.

Differential coupling of the sphingosine 1-phosphate receptors Edg-1, Edg-3, and H218/Edg-5 to the G(i), G(q), and G(12) families of heterotrimeric G proteins

J. Biol. Chem.

(1999)

J. Alblas et al.

C-terminal truncation of the neurokinin-2 receptor causes enhanced and sustained agonist-induced signaling

J. Biol. Chem.

(1995)

K. Jalink et al.

Lysophosphatidic acid, but not phosphatidic acid, is a potent Ca²⁺-mobilizing stimulus for fibroblasts

J. Biol. Chem.

(1990)

G.A. Piazza et al.

Lysophosphatidic acid induction of transforming growth factors alpha and beta: Modulation of proliferation and differentiation in cultured human keratinocytes and mouse skin

Exp. Cell Res.

(1995)

N. Hisano et al.

Induction and suppression of endothelial cell apoptosis by sphingolipids: A possible in vitro model for cell–cell interactions between platelets and endothelial cells

Blood

(1999)

S. Saito

Effects of lysophosphatidic acid on primary cultured chick neurons

Neurosci. Lett.

(1997)

A. Gohla et al.

The G-protein G13 but not G12 mediates signaling from lysophosphatidic acid receptor via epidermal growth factor receptor to Rho

J. Biol. Chem.

(1998)

G.A. Ramakers et al.

Regulation of astrocyte morphology by RhoA and lysophosphatidic acid

Exp. Cell Res.

(1998)

J.L. Ridet et al.

Reactive astrocytes: Cellular and molecular cues to biological function

Trends Neurosci.

(1997)

F. Imamura et al.

Induction of in vitro tumor cell invasion of cellular monolayers by lysophosphatidic acid or phospholipase D

Biochem. Biophys. Res. Commun.

(1993)

K. Yoshioka et al.

Small GTP-binding protein Rho stimulates the actomyosin system, leading to invasion of tumor cells

J. Biol. Chem.

(1998)

S. Yamamura et al.

Sphingosine-1-phosphate inhibits actin nucleation and pseudopodium formation to control cell motility of mouse melanoma cells

FEBS Lett.

(1996)

F. Wang et al.

Involvement of focal adhesion kinase in inhibition of motility of human breast cancer cells by sphingosine 1-phosphate

Exp. Cell Res.

(1999)

S. Kawa et al.

Inhibition of chemotactic motility and trans-endothelial migration of human neutrophils by sphingosine 1-phosphate

FEBS Lett.

(1997)

Q. Zhang et al.

Sphingosine 1-phosphate stimulates fibronectin matrix assembly through a Rho-dependent signal pathway

Blood

(1999)

J. Chun et al.

A growing family of receptor genes for lysophosphatidic acid (LPA) and other lysophospholipids (LPs)

Cell Biochem. Biophys.

(1999)

E.J. Goetzl et al.

Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate

FASEB J.

(1998)

S. Spiegel

Sphingosine 1-phosphate: A prototype of a new class of second messengers

J. Leukocyte Biol.

(1999)

T. Hla et al.

Sphingosine-1-phosphate: Extracellular mediator or intracellular second messenger

Biochem. Pharmacol.

(1999)

T. Eichholtz et al.

The bioactive phospholipid lysophosphatidic acid is released from activated platelets

Biochem. J.

(1993)

Y. Igarashi et al.

Sphingosine 1-phosphate is a blood constituent released from activated platelets, possibly playing a variety of physiological and pathophysiological roles

Acta Biochim. Pol.

(1998)

P. Valet et al.

Alpha2-adrenergic receptor-mediated release of lysophosphatidic acid by adipocytes. A paracrine signal for preadipocyte growth

J. Clin. Invest.

(1998)

A. Olivera et al.

Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens

Nature

(1993)

J.R. Van Brocklyn et al.

Dual actions of sphingosine-1-phosphate: Extracellular through the Gi-coupled receptor Edg-1 and intracellular to regulate proliferation and survival

J. Cell Biol.

(1998)

D. Meyer zu Heringdorf et al.

Sphingosine kinase-mediated Ca²⁺ signaling by G-protein-coupled receptors

EMBO J.

(1998)

K.J. Einspahr et al.

Concurrent changes in Dunaliella salina ultrastructure and membrane phospholipid metabolism after hyperosmotic shock

J. Cell Biol.

(1988)

Cited by (373)

Magic shotgun over magic bullet for treatment of ovarian cancer via polymeric nanoparticles
2023, Journal of Drug Delivery Science and Technology
According to the world cancer research fund international (WCRFI), ovarian cancer is considered the 8th-most prevalent form of cancer in women, with approximately 313,000 new cases recorded in 2020. The high emergence of chemoresistance, recurrence, and harmful side effects imposed by currently existing treatments, viz., chemotherapy, radiation therapy, and surgical debulking, generates a void for effective therapeutic options. The traditional paradigm of a single target approach, based on Ehrlich's magic bullets, for a disease with multiple complexities has been challenged by the new concept of magic shotguns, which simultaneously alleviates multiple causes and pathways responsible for the disease. The relevance of various natural and synthetic polymeric nanoparticles for the delivery of anti-cancer agent(s) with the capacity to target multiple active receptors can provide an effective therapy coupled with a lower incidence of recurrence. Such systems offer high synergy, low dose dependent side effects, overcome multidrug resistance, and benefit the metastatic stage of ovarian cancer treatment. As a practical matter, it would be advantageous to create a "magic shotgun" that can deliver promiscuous chemotherapeutic agents, encased in polymeric nanoparticles, to multiple targets with significantly improved biopharmaceutical attributes over existing conventional therapy. In this article, we discuss in detail the nanotechnology-based approach to treating ovarian cancer, including the genetic pathways involved and the future prospects of the magic shotgun approach.
Extracellular vesicles as mediators of cell-cell communication in ovarian cancer and beyond – A lipids focus
2023, Cytokine and Growth Factor Reviews
Extracellular vesicles (EVs) are messengers that carry information in the form of proteins, lipids, and nucleic acids and are not only essential for intercellular communication but also play a critical role in the progression of various pathologies, including ovarian cancer. There has been recent substantial research characterising EV cargo, specifically, the lipid profile of EVs. Lipids are involved in formation and cargo sorting of EVs, their release and cellular uptake. Numerous lipidomic studies demonstrated the enrichment of specific classes of lipids in EVs derived from cancer cells suggesting that the EV associated lipids can potentially be employed as minimally invasive biomarkers for early diagnosis of various malignancies, including ovarian cancer. In this review, we aim to provide a general overview of the heterogeneity of EV, biogenesis, their lipid content, and function in cancer progression focussing on ovarian cancer.
Coordination of rigidity modulation and targeting ligand modification on orally-delivered nanoparticles for the treatment of liver fibrosis
2022, Journal of Controlled Release
Although the individual role of ligand modification or rigidity modulation on oral administration of nanoparticle (NP) has been investigated, how they mutually affect each other remains to be elucidated. Here, we fabricated different rigidity NP with or without surface decoration of FcBP, a neonatal Fc receptor domain-binding peptide. In vitro studies showed that, without FcBP modification, stiff NP had higher transcytosis efficiency across the epithelium than softer NP, due to the different endocytosis mechanisms, intracellular trafficking routes, and exocytosis rate. Notably, after FcBP modification, such difference was narrowed, in a manner that was more favorable for softer NP to “catch up” with stiff NP, suggesting ligand modification was more conducive to exert transcytosis-promoting efficacy on softer NP. In vivo experiments demonstrated that, for ligand-free NP, high rigidity was required for efficient oral absorption and liver distribution. Further FcBP modification decreased that “rigidity threshold”, and expanded the feasible rigidity range from stiff NP to softer NP. Upon oral administration, FcBP-modified dexamethasone-loaded softer NP achieved a therapeutic efficacy comparable with stiff NP on alleviating liver fibrosis. Collectively, our study highlighted the necessity of coordinating ligand modification and rigidity modulation for oral drug delivery.
S1P signaling, its interactions and cross-talks with other partners and therapeutic importance in colorectal cancer
2021, Cellular Signalling
Sphingosine-1-Phosphate (S1P) plays an important role in normal physiology, inflammation, initiation and progression of cancer. Deregulation of S1P signaling causes aberrant proliferation, affects survival, leads to angiogenesis and metastasis. Sphingolipid rheostat is crucial for cellular homeostasis. Discrepancy in sphingolipid metabolism is linked to cancer and drug insensitivity. Owing to these diverse functions and being a potent mediator of tumor growth, S1P signaling might be a suitable candidate for anti-tumor therapy or combination therapy. In this review, with a focus on colorectal cancer we have summarized the interacting partners of S1P signaling pathway, its therapeutic approaches along with the contribution of S1P signaling to various cancer hallmarks.
Expression of lysophosphatidic acid receptor 1 in the adult female mouse pituitary gland
2021, Neuroscience Letters
Lysophosphatidic acid receptor 1 (LPA₁) is a receptor of lysophosphatidic acid (LPA). The present study investigated Lpar₁ mRNA expression in the mouse pituitary gland by RT-PCR, in situ hybridization, and immunohistochemistry. Lpar₁ mRNA was abundantly expressed in the pituitary gland. In situ hybridization and immunohistochemistry revealed over 90 % of a common glycoprotein α-subunit, luteinizing hormone β-subunit, and thyroid-stimulating hormone β-subunit immunoreactive cells co-expressed Lpar₁ mRNA in the anterior pituitary gland, but few growth hormone, adrenocorticotropic hormone, and prolactin cells co-expressed Lpar₁. Furthermore, Lpar₁ mRNA levels in the pituitary gland were increased after ovariectomy and decreased after E2 administration. These results demonstrate that LPA₁-mediated signaling may play physiological roles in gonadotropes and thyrotropes in the mouse pituitary gland.
Effects of LPA2R, LPA3R, or EP4R agonists on luteal or endometrial function in vivo or in vitro and sirtuin or EP1R, EP2R, EP3R or EP4R agonists on endometrial secretion of PGE and PGF<inf>2α</inf> in vitro
2017, Theriogenology
Citation Excerpt :
In addition, DP (LPA2R) or OMPT (LPA3R) agonists did not inhibit progesterone secretion by ovine luteal tissue in vitro reported herein indicating that LPA2R or LPA3R agonists are not involved in luteolysis. This is in contrast to reports that luteal mRNA expression of LPA2R increased transiently in bovine and that LPA inhibited LH-stimulated progesterone secretion by these cells in vitro via inhibition of cAMP production [29–31]. Instead, DP (LPA2R) may enhance luteal function, since the LPA2R agonist in vivo increased luteal mRNA expression of LHR, and OMPT the LPA3R agonist did not alter luteal mRNA expression of LHR.
In previous work, an EP2 prostanoid receptor (EP2R) agonist in vivo increased mRNA expression of luteal LH receptors (LHR), unoccupied and occupied luteal; LHR, and circulating progesterone, while an EP3R or FPR agonist decreased; mRNA expression of luteal LHR, unoccupied and occupied luteal LHR, and; circulating progesterone. An EP4R and lysophosphatidic acid (LPA) LPA2R and LPA3R agonists were reported to inhibit luteal function and sirtuins have been proposed to increase prostaglandin synthesis. The objectives were to determine; whether an EP4R, LPA2R, or LPA3R agonist affect ovine luteal function in vivo or; in vitro. In addition, whether sirtuin (SIRT)-1, 2, or 3; LPA2R or LPA3R; or EP1R, EP2R, EP3R, or EP4R agonists affect caruncular endometrial PGF_2α or PGE (PGE1+PGE2) secretion in vitro. Day-10 nonpregnant ewes received a single injection of Vehicle (N = 5); an LPA2R (N = 5); LPA3R (N = 6); or EP4R (N = 5) agonist given into the interstitial tissue of the ovarian vascular pedicle adjacent to the luteal-containing ovary to determine effects on circulating progesterone, mRNA expression of luteal LHR, and luteal unoccupied and occupied LHR. In addition, agonists for LPA2R, LPA3R, EP1R, EP2R, EP3R, or EP4R or SIRT-1, SIRT-2, or SIRT-3 activators were incubated with caruncular endometrial slices in vitro to determine their effect on caruncular endometrial PGF_2α, or PGE secretion. LPA2R, LPA3R, or an EP4R agonist in vivo did not affect (P ≥ 0.05) luteal weight, circulating progesterone, or occupied luteal LHR. However, an LPA2R or EP4R agonist, but; not LPA3R agonist, in vivo increased (P ≤ 0.05) mRNA expression of luteal LHR. An; LPA2R, LPA3R, or EP4R agonist increased (P ≤ 0.05) luteal unoccupied LHR, but; not occupied LHR. An LPA2R, LPA3R, or an EP4R agonist did not affect (P ≥ 0.05); luteal progesterone secretion in vitro. An LPA2R or LPA3R agonist did not affect (P ≥ 0.05) luteal PGF_2α, or PGE secretion in vitro. However, an EP4R agonist tended to decrease (P < 0.066) luteal PGF_2α secretion and increased (P ≤ 0.05) luteal PGE; secretion in vitro. EP1R, EP2R, EP3R, or an EP4R agonist did not affect (P ≥ 0.05); caruncular endometrial PGF_2α secretion in vitro. However, EP1R, EP3R, or an EP4R agonist increased caruncular endometrial PGE secretion in vitro, while two different EP2R agonists did not affect (P ≥ 0.05) caruncular endometrial PGE; secretion. A SIRT-1 activator, but not SIRT-2 or SIRT-3 activators, increased (P ≤ 0.05) caruncular endometrial PGE secretion, while sirtuin 1, 2, or 3 activators did not affect (P ≥ 0.05) caruncular endometrial PGF_2α secretion. In conclusion, receptors for EP4, LPA2, and LPA3 do not appear to be involved; in luteolysis, but EP4R and LPA2R might participate in preventing luteolysis by maintaining luteal mRNA expression for LHR and preventing loss of unoccupied luteal LHR. In addition, SIRT-1, EP1R, EP3R, and EP4R might be involved in; regulating caruncular endometrial PGE secretion, but not PGF_2α secretion.

View all citing articles on Scopus

¹: Fax: +31-20-512 1989. E-mail: [email protected].

View full text

Regular ArticleBioactive Lysophospholipids and Their G Protein-Coupled Receptors

Abstract

J. Biol. Chem.

Curr. Opin. Cell Biol.

Blood

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

Cell

Curr. Biol.

Ann. Oncol.

J. Biol. Chem.

J. Biol. Chem.

Gene

Biochem. Biophys. Res. Commun.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

Exp. Cell Res.

Blood

Neurosci. Lett.

J. Biol. Chem.

Exp. Cell Res.

Trends Neurosci.

Biochem. Biophys. Res. Commun.

J. Biol. Chem.

FEBS Lett.

Exp. Cell Res.

FEBS Lett.

Blood

A growing family of receptor genes for lysophosphatidic acid (LPA) and other lysophospholipids (LPs)

Cell Biochem. Biophys.

Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate

FASEB J.

Sphingosine 1-phosphate: A prototype of a new class of second messengers

J. Leukocyte Biol.

Sphingosine-1-phosphate: Extracellular mediator or intracellular second messenger

Biochem. Pharmacol.

The bioactive phospholipid lysophosphatidic acid is released from activated platelets

Biochem. J.

Sphingosine 1-phosphate is a blood constituent released from activated platelets, possibly playing a variety of physiological and pathophysiological roles

Acta Biochim. Pol.

Alpha2-adrenergic receptor-mediated release of lysophosphatidic acid by adipocytes. A paracrine signal for preadipocyte growth

J. Clin. Invest.

Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens

Nature

Dual actions of sphingosine-1-phosphate: Extracellular through the Gi-coupled receptor Edg-1 and intracellular to regulate proliferation and survival

J. Cell Biol.

Sphingosine kinase-mediated Ca2+ signaling by G-protein-coupled receptors

EMBO J.

Concurrent changes in Dunaliella salina ultrastructure and membrane phospholipid metabolism after hyperosmotic shock

J. Cell Biol.

Regular Article
Bioactive Lysophospholipids and Their G Protein-Coupled Receptors

Sphingosine kinase-mediated Ca²⁺ signaling by G-protein-coupled receptors